Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-338023
Filing Date
2026-08-06
Accepted
2026-08-06 16:12:29
Documents
56
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20260630.htm   iXBRL 10-Q 2071225
2 EX-31.1 trvi-ex31_1.htm EX-31.1 18102
3 EX-31.2 trvi-ex31_2.htm EX-31.2 18091
4 EX-32.1 trvi-ex32_1.htm EX-32.1 12331
5 EX-32.2 trvi-ex32_2.htm EX-32.2 12306
  Complete submission text file 0001193125-26-338023.txt   8512727

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20260630.xsd EX-101.SCH 1023113
60 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20260630_htm.xml XML 1639432
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 261249173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)